BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 9032579)

  • 21. COX-1 and COX-2 inhibition: current status and future perspective.
    Greyn J; Lauwers MH; Vanlersberghe C; Camu F
    Acta Anaesthesiol Belg; 1998; 49(3):175-83. PubMed ID: 9844704
    [No Abstract]   [Full Text] [Related]  

  • 22. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
    Linder JD; Mönkemüller KE; Davis JV; Wilcox CM
    South Med J; 2000 Sep; 93(9):930-2. PubMed ID: 11005360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COX-2 inhibitors and Celebrex: safe or suspect?
    Health News; 1999 Jun; 5(7):4. PubMed ID: 10932776
    [No Abstract]   [Full Text] [Related]  

  • 25. Mechanism of action of antiinflammatory drugs.
    Vane JR; Botting RM
    Int J Tissue React; 1998; 20(1):3-15. PubMed ID: 9561441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclooxygenase-2 inhibitors: promise or peril?
    Mengle-Gaw LJ; Schwartz BD
    Mediators Inflamm; 2002 Oct; 11(5):275-86. PubMed ID: 12467519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.
    Jones MK; Wang H; Peskar BM; Levin E; Itani RM; Sarfeh IJ; Tarnawski AS
    Nat Med; 1999 Dec; 5(12):1418-23. PubMed ID: 10581086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?
    Giovanni G; Giovanni P
    J Nephrol; 2002; 15(5):480-8. PubMed ID: 12455713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The COX-2 inhibitor NS-398 causes T-cell developmental disruptions independent of COX-2 enzyme inhibition.
    Xu H; Izon DJ; Loftin C; Spain LM
    Cell Immunol; 2001 Dec; 214(2):184-93. PubMed ID: 12088417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The multisystem adverse effects of NSAID therapy.
    James DS
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S1-7. PubMed ID: 10643174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COX-2 inhibitors. What is their place?
    McGettigan P
    Aust Fam Physician; 2000 Sep; 29(9):847-52. PubMed ID: 11008387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
    Sun Y; Tang XM; Half E; Kuo MT; Sinicrope FA
    Cancer Res; 2002 Nov; 62(21):6323-8. PubMed ID: 12414664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
    Lamarque D
    Bull Cancer; 2004 May; 91 Spec No():S117-24. PubMed ID: 15239340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The unmet anti-inflammatory needs in orthopedics.
    Trippel SB
    Am J Orthop (Belle Mead NJ); 1999 Mar; 28(3 Suppl):3-7. PubMed ID: 10193996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.
    Kurumbail RG; Stevens AM; Gierse JK; McDonald JJ; Stegeman RA; Pak JY; Gildehaus D; Miyashiro JM; Penning TD; Seibert K; Isakson PC; Stallings WC
    Nature; 1996 Dec 19-26; 384(6610):644-8. PubMed ID: 8967954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NSAIDs, Helicobacter pylori, and Pandora's Box.
    Graham DY
    N Engl J Med; 2002 Dec; 347(26):2162-4. PubMed ID: 12501230
    [No Abstract]   [Full Text] [Related]  

  • 40. Arthritis. Should you be taking a COX-2 inhibitor?
    Harv Health Lett; 2001 Nov; 27(1):1-3. PubMed ID: 11724695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.